- Ongoing, recruitingTherapeutic exploratory (Phase II)
ARGX-113-2211: Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients with primary Sjögren’s Syndrome (pSS) who complete qualifying efgartigimod pSS studies
This study is looking at how safe a new medicine called efgartigimod is for adults with primary Sjögren's Syndrome. It's for people who have already taken part in a related study on this medicine. We want to see if there are any side effects.
For: Primary Sjögren's SyndromePoland · Hungary · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ARGX-113-1803: A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
This study is looking at a new medicine called efgartigimod for adults with primary immune thrombocytopenia (ITP). It wants to see if the medicine is safe and how well it helps improve platelet counts over a long time. Researchers will check for side effects and how patients feel.
For: Primary immune thrombocytopeniaItaly · Czechia · Poland